Andy Surinach

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 9

Top Topics

Prognostic Factors

Hodgkin Lymphoma

Top Venues

Cancer medicine

Future oncology (London, England)

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Susan K Parsons, Kristina S Yu, Nicholas Liu, Supriya Kumar, Michelle A Fanale, Katie Holmes, Carlos Flores Avile, Andy Surinach, Darcy R Flora, Andrew M Evens
Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography-Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study. JCO oncology practice (2023)
John M Burke, Nicholas Liu, Kristina S Yu, Michelle A Fanale, Andy Surinach, Carlos Flores Avile, Julie Lisano, Tycel Jovelle Phillips
Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy. The oncologist (2023)
Andrew M Evens, Kristina S Yu, Nicholas Liu, Andy Surinach, Katherine Holmes, Carlos Flores Avile, Michelle A Fanale, Darcy R Flora, Susan K Parsons
Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study. Future oncology (London, England) (2023)
Kenneth H Yu, Paul Cockrum, Andy Surinach, Neil Lamarre, Shu Wang, Eileen M O'Reilly
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma. Cancer medicine (2023)
Ravi Kumar Paluri, Ashley Laursen, Joseph Gaeta, Shu Wang, Andy Surinach, Paul Cockrum
Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States. The oncologist 27 (6) (2022)
Rawad Elias, Paul Cockrum, Andy Surinach, Shu Wang, Bong Chul Chu, Armin Shahrokni
Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma. The oncologist 27 (6) (2022)
Kenneth H Yu, Muhammet Ozer, Paul Cockrum, Andy Surinach, Shu Wang, Bong Chul Chu
Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Cancer medicine (2021)
Eileen M O'Reilly, Paul Cockrum, Andy Surinach, Zheng Wu, Allison Dillon, Kenneth H Yu
Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes. Cancer medicine 9 (22) (2020)
George P Kim, Andy Surinach, Frank A Corvino, Paul Cockrum, Bruce Belanger, Laith Abushahin
Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma. Future oncology (London, England) 17 (6) (2020)